Avinger announces fda clearance of pantheris for the treatment of in-stent restenosis

New indication expands addressable market for pantheris redwood city, ca / accesswire / november 17, 2021 / avinger, inc. (nasdaq:avgr), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of peripheral artery disease (pad), today announced that it has received 510(k) clearance from the u.s. food & drug administration (fda) for a new clinical indication for the pantheris image-guided atherectomy system. this clearance allows the company to directly market pantheris for the treatment of in-stent restenosis (isr) in the lower extremity arteries.
AVGR Ratings Summary
AVGR Quant Ranking